Cognition Therapeutics, Inc(CGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CGTX Cognition Therapeutics, Inc

Not Yet Opened 11-10 16:00:00 EST

0.6702

-0.0204

-2.95%

盘后0.6868

+0.0166+2.48%

19:22 EST

High0.6907	Low0.6521	Vol367.26K
Open0.6882	D1 Closing0.6906	Amplitude5.59%
Mkt Cap63.73M	Tradable Cap57.25M	Total Shares95.09M
T/O246.28K	T/O Rate0.43%	Tradable Shares85.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CGTX","market":"US","secType":"STK","nameCN":"Cognition Therapeutics, Inc","latestPrice":0.6702,"timestamp":1794344400000,"preClose":0.6906,"halted":0,"volume":367262,"hourTrading":{"tag":"盘后","latestPrice":0.6868,"preClose":0.6702,"latestTime":"19:22 EST","volume":2669,"amount":1822.2501,"timestamp":1794356548702,"change":0.0166,"changeRate":0.024769,"amplitude":0.028051},"delay":0,"changeRate":-0.029539530842745403,"floatShares":85422005,"shares":95093746,"eps":-0.175917,"marketStatus":"Not Yet Opened","change":-0.0204,"latestTime":"11-10 16:00:00 EST","open":0.6882,"high":0.6907,"low":0.6521,"amount":246281.5635084,"amplitude":0.055893,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.175917,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794387600000},"marketStatusCode":0,"adr":0,"listingDate":1633665600000,"exchange":"NASDAQ","adjPreClose":0.6906,"preHourTrading":{"tag":"盘前","latestPrice":0.68,"preClose":0.6906,"latestTime":"09:26 EST","volume":286,"amount":196.56439659999998,"timestamp":1794320795963,"change":-0.0106,"changeRate":-0.015349,"amplitude":0.038372},"postHourTrading":{"tag":"盘后","latestPrice":0.6868,"preClose":0.6702,"latestTime":"19:22 EST","volume":2669,"amount":1822.2501,"timestamp":1794356548702,"change":0.0166,"changeRate":0.024769,"amplitude":0.028051},"volumeRatio":0.823558},"requestUrl":"/m/hq/s/CGTX/tweets","defaultTab":"tweets","newsList":[{"id":"2681768190","title":"Cognition Therapeutics Inc Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2681768190","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681768190?lang=en_us&edition=fundamental","pubTime":"2026-11-05 21:35","pubTimestamp":1793885740,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics Inc reports results for the quarter ended September 30 - Earnings SummaryCognition Therapeutics IncCGTX.OQreported a quarterly adjusted loss of 4 cents per share for the quarter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL5N46M1QR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681021536","title":"Cognition Therapeutics Reports Third-Quarter Results, Advances Zervimesine Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2681021536","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681021536?lang=en_us&edition=fundamental","pubTime":"2026-11-05 19:39","pubTimestamp":1793878761,"startTime":"0","endTime":"0","summary":"An update from Cognition Therapeutics ( ($CGTX) ) is now available. On November 3, 2026, Cognition received a Nasdaq notice stating that its common...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cognition-therapeutics-reports-third-quarter-results-advances-zervimesine-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cognition-therapeutics-reports-third-quarter-results-advances-zervimesine-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LCLG","CGTX","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681207026","title":"Cognition Therapeutics Q3 Net Loss Narrows on Higher Grant Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2681207026","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681207026?lang=en_us&edition=fundamental","pubTime":"2026-11-05 19:20","pubTimestamp":1793877643,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics Q3 net loss narrows on higher grant incomeOverviewUS neurodegenerative drug developer's Q3 net loss narrowed from prior yearResearch and development expenses rose on higher tria","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL2N46M0H7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","BK4007","NBIX","LU2065169927.USD","LU0154245673.USD","LU0889565916.HKD","LU2488822045.USD","LYEL","LU2065170008.USD","LU2324357040.USD","LU2065171311.SGD","LU0320765992.SGD","BK4539","LU2065171402.SGD","LU0823416689.USD","LU0154245756.USD","CGTX","LU0109394709.USD","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681025280","title":"Cognition Therapeutics Q3 EPS $(0.04) Beats $(0.07) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2681025280","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681025280?lang=en_us&edition=fundamental","pubTime":"2026-11-05 19:03","pubTimestamp":1793876636,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 42.86 percent. This is a 33.33 percent increase over losses of $(0.06) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/62907545/cognition-therapeutics-q3-eps-0-04-beats-0-07-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681256320","title":"Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2681256320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681256320?lang=en_us&edition=fundamental","pubTime":"2026-11-05 19:00","pubTimestamp":1793876401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nTUA6D531F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681102568","title":"Cognition Therapeutics Q3 Income from Operations USD -7.377 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2681102568","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681102568?lang=en_us&edition=fundamental","pubTime":"2026-11-05 19:00","pubTimestamp":1793876401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nPLXLGFKFJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680523817","title":"Cognition Therapeutics to Host Third-Quarter Financial Results Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2680523817","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680523817?lang=en_us&edition=fundamental","pubTime":"2026-11-02 20:30","pubTimestamp":1793622625,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics to Host Third-Quarter Financial Results CallCognition Therapeutics will host its third-quarter 2026 results call and webcast on November 5, 2026, at 8:30 a.m. ET.The event will ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nNDLbRMSWs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014021.USD","BK4112","BCDF","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014013.SGD","IE00BN0W2V16.EUR","NDAQ","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","CGTX","BK4588","IE00BQXX3D17.EUR","BK4007","LU2210150020.SGD","IE00BQXX3F31.USD","IE00BN0W2W23.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4585","SG9999014039.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677790921","title":"Robinhood - Robinhood Ventures Fund I Invests $10 Million in Cognition","url":"https://stock-news.laohu8.com/highlight/detail?id=2677790921","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677790921?lang=en_us&edition=fundamental","pubTime":"2026-10-23 20:00","pubTimestamp":1792756859,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nFWN4692BO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","LU1861558580.USD","LU1861559042.SGD","HOOG","BK4127","HOOI","HOOD","HOOY","CRPT","BK4539","HOII","BPAY","HODU","BK4007","HOOZ","HOOX","HOYY","CGTX","IAI","FINX","HOOC","HOOW","BLCK","ROBN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677595413","title":"Cognition Rises After FDA Backs Late-Stage Trial Plan for Dementia Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2677595413","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677595413?lang=en_us&edition=fundamental","pubTime":"2026-10-22 18:51","pubTimestamp":1792666260,"startTime":"0","endTime":"0","summary":"BUZZ-Cognition rises after FDA backs late-stagetrial plan for dementia drug** Shares of drug developer Cognition TherapeuticsCGTX.Orise 7% to 79 cents premarket** Cognition Therapeuticssaysthe US FDA ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261022:nL6N4680TR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677795138","title":"Cognition Therapeutics aligns with FDA on Phase 3 trial of zervimesine","url":"https://stock-news.laohu8.com/highlight/detail?id=2677795138","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677795138?lang=en_us&edition=fundamental","pubTime":"2026-10-22 18:15","pubTimestamp":1792664159,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics (CGTX) has aligned with the U.S. FDA on key elements of a Phase 3 study in dementia with Lewy bodies including patient selec...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cognition-therapeutics-aligns-with-fda-on-phase-3-trial-of-zervimesine-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cognition-therapeutics-aligns-with-fda-on-phase-3-trial-of-zervimesine-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","BK4007","CGTX","BK4585","PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677264956","title":"Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (Ct1812) in Dementia with Lewy Bodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2677264956","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677264956?lang=en_us&edition=fundamental","pubTime":"2026-10-22 18:00","pubTimestamp":1792663200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261022:nTUA6LN3CM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677596639","title":"Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2677596639","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677596639?lang=en_us&edition=fundamental","pubTime":"2026-10-22 18:00","pubTimestamp":1792663200,"startTime":"0","endTime":"0","summary":"PURCHASE, N.Y., Oct.  22, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/22/3386131/0/en/cognition-therapeutics-announces-alignment-with-fda-on-pivotal-phase-3-trial-of-zervimesine-ct1812-in-dementia-with-lewy-bodies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345774631.USD","LU0205193047.USD","LU0345774391.USD","LABU","LU0240877869.USD","BK4588","BK4585","LU0205194284.USD","LU0240878834.USD","LU0348723411.USD","DLB","CGTX","BK4007","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675432557","title":"Cognition Therapeutics: Patent Extension and Pivotal CNS Catalysts Support Buy Rating with Unchanged $3 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2675432557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675432557?lang=en_us&edition=fundamental","pubTime":"2026-10-14 23:35","pubTimestamp":1791992121,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cognition Therapeutics today and set a price target of $3.00. Ram Selvaraju has gi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cognition-therapeutics-patent-extension-and-pivotal-cns-catalysts-support-buy-rating-with-unchanged-3-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cognition-therapeutics-patent-extension-and-pivotal-cns-catalysts-support-buy-rating-with-unchanged-3-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675235335","title":"Cognition Therapeutics issued patent extending protection for zervimesine","url":"https://stock-news.laohu8.com/highlight/detail?id=2675235335","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675235335?lang=en_us&edition=fundamental","pubTime":"2026-10-13 18:11","pubTimestamp":1791886308,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics (CGTX) announced that the United States Patent and Trademark Office has granted the company a patent covering a novel crysta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cognition-therapeutics-issued-patent-extending-protection-for-zervimesine-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cognition-therapeutics-issued-patent-extending-protection-for-zervimesine-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CGTX","USRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675561358","title":"Cognition Therapeutics Wins US Patent for New Crystalline Form of Zervimesine Through 2045","url":"https://stock-news.laohu8.com/highlight/detail?id=2675561358","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675561358?lang=en_us&edition=fundamental","pubTime":"2026-10-13 18:01","pubTimestamp":1791885716,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics wins US patent for new crystalline form of zervimesine through 2045Cognition Therapeutics won a U.S. patent covering a new crystalline form of its lead candidate zervimesine (CT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nNDL5Xvx5g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","BK4007","IE00B64PRP62.GBP","BK4112","IE00BKPKM429.USD","SG9999014013.SGD","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SG9999014039.USD","LU0314104364.USD","BK4585","LU2210150020.SGD","BK4588","BCDF","CGTX","SG9999014021.USD","IE00BQXX3D17.EUR","IE00B3QW5Z07.USD","SG9999014005.SGD","NDAQ","IE00BN0W2T93.GBP","LU2095319765.USD","LU2210149790.SGD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675894358","title":"Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (Ct1812) Through 2045","url":"https://stock-news.laohu8.com/highlight/detail?id=2675894358","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675894358?lang=en_us&edition=fundamental","pubTime":"2026-10-13 18:00","pubTimestamp":1791885655,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nFWN45Z0PR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675358379","title":"Cognition Therapeutics - FDA Meeting Scheduled Next Week for Dlb Program; Manufacturing Planned Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2675358379","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675358379?lang=en_us&edition=fundamental","pubTime":"2026-10-13 18:00","pubTimestamp":1791885655,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nFWN45Z0PR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675358370","title":"Cognition Therapeutics - Patent Expires in 2045; May be Extended up to Five Years upon FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2675358370","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675358370?lang=en_us&edition=fundamental","pubTime":"2026-10-13 18:00","pubTimestamp":1791885655,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nFWN45Z0PR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675139358","title":"Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045","url":"https://stock-news.laohu8.com/highlight/detail?id=2675139358","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675139358?lang=en_us&edition=fundamental","pubTime":"2026-10-13 18:00","pubTimestamp":1791885600,"startTime":"0","endTime":"0","summary":"- An additional five years of patent protection may be possible through a standard extension -PURCHASE, N.Y., Oct.  13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/13/3379471/0/en/cognition-therapeutics-announces-issuance-of-composition-of-matter-patent-extending-protection-for-zervimesine-ct1812-through-2045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0205193047.USD","LU0345774391.USD","CGTX","LU0240878834.USD","BK4097","LU0345774631.USD","LU0240877869.USD","LU0205194284.USD","BK4007","DLB","USRD","LU0348723411.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671219930","title":"Cognition Therapeutics schedules Type C meeting with FDA for trial of CT1812","url":"https://stock-news.laohu8.com/highlight/detail?id=2671219930","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671219930?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:36","pubTimestamp":1790681804,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics (CGTX) announced that a Type C meeting with the U.S. Food and Drug Administration, FDA, Division of Neurology has been sched...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cognition-therapeutics-schedules-type-c-meeting-with-fda-for-trial-of-ct1812-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cognition-therapeutics-schedules-type-c-meeting-with-fda-for-trial-of-ct1812-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CGTX","BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cogrx.com","stockEarnings":[{"period":"1week","weight":-0.0419},{"period":"1month","weight":-0.2357},{"period":"3month","weight":-0.3556},{"period":"6month","weight":-0.4415},{"period":"1year","weight":-0.6011},{"period":"ytd","weight":-0.5036}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":-0.0368},{"period":"3month","weight":-0.0292},{"period":"6month","weight":0.0023},{"period":"1year","weight":0.1005},{"period":"ytd","weight":0.0997}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.060065},{"month":2,"riseRate":0,"avgChangeRate":-0.189802},{"month":3,"riseRate":0.2,"avgChangeRate":-0.073136},{"month":4,"riseRate":0.8,"avgChangeRate":0.125839},{"month":5,"riseRate":0.4,"avgChangeRate":-0.077033},{"month":6,"riseRate":0.2,"avgChangeRate":-0.035976},{"month":7,"riseRate":0.2,"avgChangeRate":0.013942},{"month":8,"riseRate":0.6,"avgChangeRate":0.607158},{"month":9,"riseRate":0,"avgChangeRate":-0.199569},{"month":10,"riseRate":0.4,"avgChangeRate":-0.044939},{"month":11,"riseRate":0.166667,"avgChangeRate":0.077402},{"month":12,"riseRate":0.4,"avgChangeRate":0.102692}],"exchange":"NASDAQ","name":"Cognition Therapeutics, Inc","nameEN":"Cognition Therapeutics, Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cognition Therapeutics, Inc(CGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cognition Therapeutics, Inc(CGTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cognition Therapeutics, Inc,CGTX,Cognition Therapeutics, Inc股票,Cognition Therapeutics, Inc股票老虎,Cognition Therapeutics, Inc股票老虎国际,Cognition Therapeutics, Inc行情,Cognition Therapeutics, Inc股票行情,Cognition Therapeutics, Inc股价,Cognition Therapeutics, Inc股市,Cognition Therapeutics, Inc股票价格,Cognition Therapeutics, Inc股票交易,Cognition Therapeutics, Inc股票购买,Cognition Therapeutics, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cognition Therapeutics, Inc(CGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cognition Therapeutics, Inc(CGTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}